Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Newsfilter
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like EOLS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EOLS is 19.25 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.800
Low
18.00
Averages
19.25
High
20.00
Current: 4.800
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
Continue Reading
Evolus Provides 2026 Net Revenue Guidance, Forecasts 13% Growth
- Strong 2025 Performance: Evolus anticipates fourth-quarter net revenues between $88.6 million and $90.6 million for 2025, reflecting a 12% to 15% year-over-year growth, indicating the company's ability to gain market share in a competitive environment.
- Sustained Profitability: The company reaffirms a positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a significant milestone in achieving sustainable profitability, which is expected to continue into 2026.
- 2026 Revenue Guidance: Evolus projects net revenues for 2026 to be between $327 million and $337 million, representing an 11% to 13% growth from preliminary 2025 results, showcasing the company's confidence in future market growth.
- Long-Term Financial Outlook: Evolus updates its 2028 financial outlook, projecting total net revenues between $450 million and $500 million, reflecting a 15% to 19% CAGR, underscoring the strategic success in international market expansion and product diversification efforts.
Continue Reading